Three Seasons Wealth LLC Makes New $444,000 Investment in 10x Genomics, Inc. (NASDAQ:TXG)

Three Seasons Wealth LLC purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 30,948 shares of the company’s stock, valued at approximately $444,000.

A number of other hedge funds have also modified their holdings of the stock. Signaturefd LLC grew its stake in 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after buying an additional 1,299 shares during the last quarter. Sound Income Strategies LLC grew its stake in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after buying an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in 10x Genomics in the fourth quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. raised its position in 10x Genomics by 817.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after acquiring an additional 4,324 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TXG shares. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Stifel Nicolaus cut their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $25.00 to $12.00 in a research note on Thursday, February 13th. JPMorgan Chase & Co. cut their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Finally, Barclays decreased their target price on 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.79.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares in the company, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

NASDAQ:TXG opened at $8.31 on Friday. The firm’s 50-day moving average is $9.55 and its 200-day moving average is $13.19. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -5.47 and a beta of 2.01. 10x Genomics, Inc. has a 52-week low of $6.78 and a 52-week high of $29.37.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Equities analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.